IP Library Granted Patent US 8,900,595
Granted Patent B2
US 8,900,595 · App. 12/245,296 · Granted Dec 2, 2014

Filovirus vectors and noninfectious filovirus-based particles

Inventors: Yoshihiro Kawaoka (Middleton, WI); Luke D. Jasenosky (Madison, WI); Gabriele Neumann (Madison, WI)
Assignee: Wisconsin Alumni Research Foundation
C07K14/005C12N15/86C12N2760/14123C12N2760/14143A61K2039/525C12N2810/6072C12N2760/14145C12N2760/14122
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,900,595
App. No.
12/245,296
Granted
Dec 2, 2014
Kind
B2
Abstract

Cloned filovirus genomic cDNA and methods of using the cDNA are provided. Further provided are noninfectious lipid encapsulated filovirus-based particles.

Claims (7)

1. A method to prepare a vaccine comprising filamentous filovirus-like particles, comprising: isolating filamentous filovirus-like particles from a mammalian cell contacted with a vector comprising a promoter operably linked to a DNA segment encoding a filovirus matrix protein and a vector comprising a promoter operably linked to a DNA segment encoding a filovirus glycoprotein; and preparing a vaccine comprising an amount of the isolated filamentous filovirus-like particles effective to induce an immune response.

2. The method of claim 1 wherein the cell is further contacted with a vector comprising a promoter operably linked to a DNA segment encoding a protein of interest.

3. The method of claim 1 wherein the filovirus matrix protein is an Ebola virus matrix protein.

4. A method to prepare a vaccine comprising filamentous filovirus-like particles, comprising: isolating filamentous filovirus-like particles from a mammalian cell contacted with a vector comprising a promoter operably linked to a DNA segment encoding a filovirus matrix protein and a vector comprising a promoter operably linked to a DNA segment encoding a filovirus glycoprotein; and preparing a vaccine comprising an amount of the isolated filamentous filovirus-like particles effective to induce an immune response, wherein the glycoprotein is a heterologous filovirus glycoprotein.

5. The method of claim 1 wherein the filovirus matrix protein comprises the amino acid motif PPAY at positions corresponding to positions 10 to 13 of SEQ ID NO:3.

6. A vaccine comprising the isolated filovirus-like particles prepared by the method of claim 1 .

7. A vaccine comprising isolated filovirus-like particles comprising filovirus matrix protein and filovirus glycoprotein.

Assignments (1)
CONFIRMATORY LICENSE Recorded Mar 14, 2018
From: UNIVERSITY OF WISCONSIN-MADISON
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 045584/0651 →
Continuity (4)
Continuation 11654863 · Jan 18, 2007
Division 10353856 · Jan 29, 2003
Provisional Application 60353972 · Jan 31, 2002
Related Publication 20100080825A1 · Apr 1, 2010